However, the clinicopathological and prognostic significance of TBX4 for PDAC patients have not been well characterized; most resectable pancreatic cancer are in stage II, and there is very little information on the prognosis of this subgroup of PDAC patients. Here, TBX4 is linked to pancreatic neoplasm.